Skip to Content
Søk Menu
9 – 12. SEPTEMBER 2023

Følg med når vi dekker WCLC 2023 | World Conference on Lung Cancer

Seneste MEDtalk fra WCLC2020

WCLC2020: Pembrolizumab plus chemotherapy provided durable clinical benefit in patients with metastatic squamous NSCLC

  • / Martin Reck

Gå ikke glipp av det nyeste fra Onkologi

Registrer deg og få nye artikler, MEDtalks, profesjonelle tester og tidsskrifter i din innboks

Få adgang

WCLC2020: Pembrolizumab with chemo-radiation therapy showed promising antitumor activity in unresectable, locally advanced, stage III NSCLC

/ Martin Reck
WCLC20NSCLC Play the Video

WCLC2020: Opløftende data for patienter med recidiverende malign mesotheliom

/ Jens Benn Sørensen
WCLC20 Play the Video

WCLC2020: Pembrolizumab significantly improved 5-year survival in patients with previously treated advanced NSCLC

/ Roy S. Herbst
WCLC20NSCLC Play the Video

WCLC2020: COVID-19 outcomes in patients with thoracic malignancies

/ Umit Tapan
COVID-19WCLC20 Play the Video

WCLC2020: Pre-operative treatment with atezolizumab in untreated stage IB-IIIB resectable NSCLC

/ Jay M. Lee
WCLC20NSCLC Play the Video

WCLC2020: Combining ipilimumab plus pembrolizumab did not add clinical benefit for patients with NSCLC

/ Michael Boyer
WCLC20NSCLC Play the Video

WCLC2020: Fewer patients with lung cancer diagnosed during the COVID-19 pandemic

/ Roxana Reyes
LungekreftCOVID-19WCLC20 Play the Video

Abstracts fra WCLC2020

12 months data from KEYNOTE-799 confirm promising response rates with pembrolizumab in combination with chemo-radiation therapy for locally advanced NSCLC

  • / BestPractice Nordic

Har du en idé til en artikkel?

Send et forslag til redaksjonen

Send mail til redaksjonen

Promising results with neoadjuvant atezolizumab for stage IB-IIIB NSCLC

/ BestPractice Nordic
WCLC20NSCLC

Nivolumab monotherapy is an effective treatment option for recurrent malignant mesothelioma

/ BestPractice Nordic
WCLC20

KEYNOTE-598 confirms current standard of care in metastatic 1L NSCLC patients with PD-L1 TPS ≥50%

/ BestPractice Nordic
WCLC20NSCLC

Få tilsendt tidsskriftet BestPractice Nordic gratis

Registrer deg eller oppdater profilen din her

Registrer deg

Onkologi / Hematologi • Nr. 4 • 2021

  • Nytt fra SABCS
  • Lungekreft
  • Nytt fra ASH
  • Myelomatose
Få tilgang

Mer fra WCLC2020

Post hoc analysis shows a clear correlation between high expression of PDL1 and efficacy of cemiplimab

/ BestPractice Nordic
WCLC20

KRAS inhibitor sotorasib may become the new standard for advanced NSCLC with KRAS mutations

/ BestPractice Nordic
WCLC20NSCLC

The COVID-19 pandemic results in delays in diagnosis and more severe disease for people with lung cancer

/ Roxana Reyes
LungekreftCOVID-19WCLC20

Increasing lung cancer cases in never-smokers

/ BestPractice Nordic
LungekreftWCLC20
Back to top